<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18105" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bacteriostatic Antibiotics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Loree</surname>
            <given-names>John</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lappin</surname>
            <given-names>Sarah L.</given-names>
          </name>
          <aff>Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>John Loree declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarah Lappin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18105.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The term "bacteriostatic antibiotics" is used to describe medications whose mechanism of action stalls bacterial cellular activity without directly causing bacterial death. The mechanisms of action of these antimicrobials are broad, and they generally require patients' to have functional immune systems to function optimally. This activity outlines the indications, mechanisms, and contraindications of bacteriostatic antimicrobials in treating bacterial infections and other key factors pertinent to members of the healthcare team treating patients with bacterial infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of various bacteriostatic antimicrobials.</p></list-item><list-item><p>Describe the indications for different bacteriostatic antimicrobials.</p></list-item><list-item><p>Review the toxicity of bacteriostatic antimicrobials.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance the use of bacteriostatic antimicrobials.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18105&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18105">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18105.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bacteriostatic antimicrobials, a term generally used to describe antimicrobials that function via inhibition of bacterial protein synthesis, have many indications in medicine according to their mechanisms of action. Due to merely inhibiting further growth of bacteria, bacteriostatic antimicrobials require a functioning host immune system to fully clear overgrowth. Due to this effect, however, observational studies have shown that there is a lower incidence of toxic shock and more tolerable side effect profiles.<xref ref-type="bibr" rid="article-18105.r1">[1]</xref><xref ref-type="bibr" rid="article-18105.r2">[2]</xref><xref ref-type="bibr" rid="article-18105.r3">[3]</xref><xref ref-type="bibr" rid="article-18105.r4">[4]</xref> The following classes and specific antimicrobials are generally bacteriostatic: tetracyclines, macrolides, clindamycin, trimethoprim/sulfamethoxazole, linezolid, and chloramphenicol. However, the routine clinical use of chloramphenicol has fallen out of favor in recent years because of side effects.</p>
        <p>The indications for tetracycline antimicrobials are extremely broad. As one of the oldest classes of antimicrobials, tetracyclines have demonstrated good activity against gram-positive, gram-negative, atypical, and spirochete bacteria.<xref ref-type="bibr" rid="article-18105.r5">[5]</xref><xref ref-type="bibr" rid="article-18105.r6">[6]</xref> While older tetracyclines (tetracycline, doxycycline) have significant resistance developed in more common pathogens, they retain good activity against atypical pathogens.<xref ref-type="bibr" rid="article-18105.r3">[3]</xref><xref ref-type="bibr" rid="article-18105.r5">[5]</xref><xref ref-type="bibr" rid="article-18105.r6">[6]</xref>&#x000a0;However, newer agents within this class (tigecycline) are seeing increasing use in the treatment of multiresistant pathogens due to low rates of resistance.<xref ref-type="bibr" rid="article-18105.r3">[3]</xref> Additionally, due to their wide spectrum of activity and predictable and comparatively tolerable toxicity profile, these agents are popular in the outpatient setting.<xref ref-type="bibr" rid="article-18105.r3">[3]</xref></p>
        <p>The indications for macrolide antimicrobials are dependent upon the specific macrolide antimicrobial in question. There are three primary antimicrobials within this class: erythromycin, clarithromycin, and azithromycin.<xref ref-type="bibr" rid="article-18105.r7">[7]</xref><xref ref-type="bibr" rid="article-18105.r8">[8]</xref> Erythromycin has poor activity against gram-negative and anaerobic organisms. However, it is extremely effective against atypical pathogens and has some activity against <italic toggle="yes">Neisseria spp</italic>. Clarithromycin has a similar spectrum of activity to erythromycin, with additional activity against some staph and strep species.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref> Azithromycin generally has less activity against most common gram-positive and negative pathogens, but it demonstrates higher efficacy against atypical agents.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref><xref ref-type="bibr" rid="article-18105.r8">[8]</xref></p>
        <p>Clindamycin is an antimicrobial that has gained many indications. In a 1996 review of the literature concerning the drug, indications for it include the following uses: skin and soft tissue infections (including diabetic foot), osteomyelitis and septic arthritis, recurrent streptococcal pharyngitis, anaerobic lung infections, and as an alternative for intra-abdominal and pelvic infections.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref>&#x000a0;However, it has poor activity in the bloodstream and is not a recommended therapy in septic patients or those with most gram-negative infections.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref><xref ref-type="bibr" rid="article-18105.r10">[10]</xref><xref ref-type="bibr" rid="article-18105.r11">[11]</xref></p>
        <p>Trimethoprim/sulfamethoxazole previously saw use as the primary outpatient antimicrobial for a wide variety of infections. However, due to the emergence of widespread resistance, it has lost its utility for empiric coverage of infection in the outpatient setting.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref>&#x000a0;Currently, trimethoprim/sulfamethoxazole indications include the treatment of uncomplicated cystitis in patients without recent antimicrobial use, hospitalization, or recurrent UTI in the past year, as well as empiric treatment of non-bloody infectious diarrhea.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Due to high resistance in strep and staph species, it is no longer the recommended agent in respiratory or skin/soft tissue infection.</p>
        <p>Additionally,&#x000a0;trimethoprim/sulfamethoxazole is one of the agents of choice to prevent HIV/AIDS-associated infections, specifically&#x000a0;<italic toggle="yes">pneumocystis&#x000a0;</italic>pneumonia (<italic toggle="yes">P. jiroveci</italic>). Its recommendations include its use as a prophylactic agent in patients with CD4 count less than 200 cells/microliter.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref></p>
        <p>Linezolid, first gaining widespread use in the 2000s, has broad activity against most gram-positive organisms.<xref ref-type="bibr" rid="article-18105.r13">[13]</xref><xref ref-type="bibr" rid="article-18105.r14">[14]</xref><xref ref-type="bibr" rid="article-18105.r15">[15]</xref>&#x000a0;Due in large part to its expense, as well as efforts to protect it against developing resistance at large, its primary use is for the treatment of multi-drug resistant gram-positive infections. It has poor activity against gram-negative and anaerobic bacteria, and clinicians should not use it in these settings. Additionally, due to its limited spectrum of activity, it should not be used as an empiric antimicrobial.&#x000a0;</p>
      </sec>
      <sec id="article-18105.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bacteriostatic antimicrobials most commonly function via the inhibition of bacterial protein synthesis pathways.</p>
        <p>As a class, the primary mechanism of action of tetracycline antimicrobials is the reversible inhibition of the 30S bacterial ribosomal subunit.<xref ref-type="bibr" rid="article-18105.r5">[5]</xref><xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r16">[16]</xref>&#x000a0;This inhibition causes the arrest of bacterial protein production, which inhibits bacterial defenses and allows for host immune cells to eliminate the offending bacteria.</p>
        <p>Macrolides function via inhibition of the larger subunit of bacterial ribosomes, the 50S subunit.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref>&#x000a0;Specifically, they bind and inhibit the translocation of amino acids out of the ribosomes, halting protein synthesis.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref>&#x000a0;Clindamycin additionally affects the 50S bacterial subunit; however, it inhibits the subunit at a different site than macrolides.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref></p>
        <p>Trimethoprim/sulfamethoxazole has been a successful antimicrobial combination formulation because each of its constituents, trimethoprim, and sulfamethoxazole, prevents effective processing of folic acid and its derivatives in bacteria.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> The thinking is that the synergistic effect of the combination significantly increases its efficacy compared to either agent alone.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Although a mounting body of research suggests that this may be untrue, the combined formulation still predominates due to a lower prevalence of resistance to the combination in the community.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref></p>
        <p>Linezolid has a unique mechanism of action compared to other antimicrobials. It binds to the P site of the 50 S ribosome, which prevents the formation of bacterial ribosomal fMet-tRNA complex and thus preventing bacterial protein synthesis.<xref ref-type="bibr" rid="article-18105.r15">[15]</xref><xref ref-type="bibr" rid="article-18105.r10">[10]</xref> As a result of this, it has no cross-resistance with other classes of antimicrobials.<xref ref-type="bibr" rid="article-18105.r10">[10]</xref><xref ref-type="bibr" rid="article-18105.r15">[15]</xref></p>
      </sec>
      <sec id="article-18105.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Tetracycline antimicrobials are administrable either orally or intravenously.<xref ref-type="bibr" rid="article-18105.r5">[5]</xref><xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref> Other preparations of tetracyclines are not common due to concerns for hypersensitivity reactions around the administration site. Most tetracyclines have poor oral bioavailability: generally less than 50%. However, doxycycline has shown to have enteral absorption exceeding 90% of the oral dose.<xref ref-type="bibr" rid="article-18105.r7">[7]</xref> The preferred intravenous preparation of tetracycline antimicrobial is doxycycline and should be given into the central venous system to reduce the risk of infusion site hypersensitivity.<xref ref-type="bibr" rid="article-18105.r5">[5]</xref><xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref></p>
        <p>While erythromycin administration is possible via the IV route, the most common formulation of macrolide antimicrobials is in oral dosage forms.<xref ref-type="bibr" rid="article-18105.r17">[17]</xref><xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref> This is due to these agents causing significant pain and discomfort around the infusion site parenterally. Additionally, intravenous macrolides have correlations with thrombophlebitis.<xref ref-type="bibr" rid="article-18105.r17">[17]</xref><xref ref-type="bibr" rid="article-18105.r18">[18]</xref></p>
        <p>Clindamycin is nearly completely absorbed orally. However, it has a relatively short half-life, requiring dosing every 6 hours.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref> It can be given intravenously to both children and adults if there is a contraindication to oral medication use.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref> Finally, clindamycin has topical preparations, most commonly used for the treatment of pelvic or vaginal infections.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref><xref ref-type="bibr" rid="article-18105.r11">[11]</xref></p>
        <p>Trimethoprim/sulfamethoxazole has available formulations on the market in both oral and intravenous forms; however, due to its indications, it is nearly universally encountered in its oral formulation.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Additionally, it has excellent absorption via the enteric system and gets excreted in its active form in the urine.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Trimethoprim, however, is more widely distributed throughout the body and is more readily excreted into the urine, causing variable concentrations of each component over time throughout the body.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref></p>
        <p>Linezolid has nearly 100% absorption orally and may be given orally or intravenously, depending on the clinical setting.<xref ref-type="bibr" rid="article-18105.r14">[14]</xref> Additionally, the drug may be taken with or without food and has a half-life allowing for twice-daily dosing. It also appears to have widespread penetration into tissue throughout the body and can be used for infections of multiple different sites.<xref ref-type="bibr" rid="article-18105.r13">[13]</xref><xref ref-type="bibr" rid="article-18105.r10">[10]</xref><xref ref-type="bibr" rid="article-18105.r15">[15]</xref></p>
      </sec>
      <sec id="article-18105.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Similar to their indications, the adverse effects of bacteriostatic antimicrobials are dependent upon the drug in question.</p>
        <p>Due to their excellent bioavailability in most tissues throughout the body, tetracyclines can easily be deposited into vascularized bones and tissues; this becomes problematic in fetuses and children less than eight years old, where tetracycline antibiotics can deposit and cause a characteristic brown discoloration of bones, which is permanent throughout life. This adverse effect is not inherently toxic and is a relative contraindication. Additionally, this effect is directly dose-dependent.<xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref></p>
        <p>Macrolide antimicrobials are significant inhibitors of CYP3A4 and have several interactions via these pathways. Specifically, they increase serum concentrations of carbamazepine, corticosteroids, cyclosporin, digoxin, theophylline, valproic acid, and warfarin.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref> Azithromycin, however, appears to have less activity on CYP3A4 and has weaker drug interactions.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref></p>
        <p>Clindamycin commonly correlates with local hypersensitivity and skin reactions, which can be severe enough to cause toxic epidermal necrolysis or Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref> Additionally, both oral and intravenous preparations of clindamycin deplete the bacterial reserve of the gut and strongly correlate with rates of <italic toggle="yes">C. difficile</italic> colitis (up to 20 to 30%) and high rates of diarrhea without underlying infection.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref></p>
        <p>Generally, trimethoprim/sulfamethoxazole is well-tolerated in both immunocompetent and immunocompromised patients. However, there are some drug-drug interactions with warfarin, methotrexate, phenytoin, digoxin, and oral contraceptives.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> For most of these agents, it increases blood concentrations, therefore increasing activity. However, it appears to inactivate oral contraceptives.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Additionally, as a sulfonamide-containing (sulfa) antimicrobial, there is a significant risk of allergy within the general population.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> A final effect of trimethoprim/sulfamethoxazole is that it causes an approximately 10% rise in serum creatinine concentrations without affecting renal function, which can mimic signs of nephrotoxicity.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref></p>
        <p>Linezolid is generally well-tolerated in the general population.<xref ref-type="bibr" rid="article-18105.r14">[14]</xref> While it has traditionally shown correlations with a risk of serotonin syndrome when given in combination with other serotonergic medications, this risk is low.<xref ref-type="bibr" rid="article-18105.r15">[15]</xref><xref ref-type="bibr" rid="article-18105.r14">[14]</xref></p>
      </sec>
      <sec id="article-18105.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The contraindications to the various bacteriostatic agents are specific to each class of drug/agent in question. Contraindications to most tetracycline antimicrobials are as follows: kidney dysfunction (except doxycycline), children less than eight, pregnant patients, and active colitis.<xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref> There are no absolute contraindications to macrolide antimicrobials. However, clinicians should pay significant attention to drug interactions, cardiac arrhythmias, and hypersensitivity related to drug breakdown products.<xref ref-type="bibr" rid="article-18105.r7">[7]</xref> Clindamycin has poor penetrance into the central nervous system and is contraindicated in a nervous system infection.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref> trimethoprim/sulfamethoxazole is contraindicated in sulfa-allergic patients. <xref ref-type="bibr" rid="article-18105.r12">[12]</xref> Linezolid has no significant contraindications; however, its use should be avoided except in resistant gram-positive infections due to antimicrobial stewardship efforts.<xref ref-type="bibr" rid="article-18105.r15">[15]</xref><xref ref-type="bibr" rid="article-18105.r10">[10]</xref></p>
      </sec>
      <sec id="article-18105.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>One advantage of most bacteriostatic antimicrobials, as a class, is that they usually do not require intensive monitoring as other classes of bactericidal drugs. Tetracycline antimicrobials do not typically require monitoring of blood drug concentrations, nor do they have an easily identifiable metabolite to monitor their activity&#x000a0;<italic toggle="yes">in vivo</italic>.<xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref> However, caution is necessary regarding patients' consumption of certain metallic elements (Ca, Al, Mg, etc.), specifically due to their inactivation by divalent and trivalent cations.<xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref> Macrolides generally do not require specific monitoring&#x000a0;<italic toggle="yes">in vivo</italic>. However, if patients are taking other agents with macrolides, corresponding concentrations of other drugs should be monitored for alterations in their activity.<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref> Clindamycin does not require laboratory monitoring for side effects; however, clinical monitoring for symptomatic diarrhea and colitis is recommended.<xref ref-type="bibr" rid="article-18105.r9">[9]</xref> There is no monitoring required for trimethoprim/sulfamethoxazole therapy.<xref ref-type="bibr" rid="article-18105.r12">[12]</xref> There is no monitoring required for linezolid.<xref ref-type="bibr" rid="article-18105.r14">[14]</xref></p>
      </sec>
      <sec id="article-18105.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In general, due to the comparatively slower mechanism of action of bacteriostatic antimicrobials, the toxicity profiles of bacteriostatic agents are generally lesser than their comparable bacteriocidal analogs.<xref ref-type="bibr" rid="article-18105.r1">[1]</xref><xref ref-type="bibr" rid="article-18105.r4">[4]</xref> Tetracycline antimicrobials, while generally well tolerated, have the following toxicities: irritant gastritis, photosensitivity, hepatotoxicity, nephrotoxicity (except doxycycline), and hypersensitivity reactions (may not be allergic).<xref ref-type="bibr" rid="article-18105.r6">[6]</xref><xref ref-type="bibr" rid="article-18105.r7">[7]</xref> The most common toxicities of macrolide antimicrobials are allergic reactions, gastrointestinal distress and promotility, cardiac arrhythmias (erythromycin, QTc prolongation), and tinnitus (erythromycin).<xref ref-type="bibr" rid="article-18105.r8">[8]</xref><xref ref-type="bibr" rid="article-18105.r9">[9]</xref> These agents, however, are generally well tolerated. Trimethoprim/sulfamethoxazole has less than 10% gastrointestinal, dermatologic toxicities and a very rare risk of aplastic anemia. The toxicity regimen of linezolid is generally limited to low risks of gastrointestinal distress, headache, and rash.<xref ref-type="bibr" rid="article-18105.r14">[14]</xref> The most significant toxicity reported in the literature for linezolid is myelosuppression and thrombocytopenia, with rates approaching 2.5%.<xref ref-type="bibr" rid="article-18105.r14">[14]</xref></p>
      </sec>
      <sec id="article-18105.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There has been a traditional bias against bacteriostatic antimicrobials for a variety of indications, particularly in more acute settings, due to a misconception that they have clinically slower rates of activity and lose efficacy.<xref ref-type="bibr" rid="article-18105.r1">[1]</xref><xref ref-type="bibr" rid="article-18105.r3">[3]</xref>&#x000a0;This perception, however, is untrue in several settings.<xref ref-type="bibr" rid="article-18105.r2">[2]</xref><xref ref-type="bibr" rid="article-18105.r1">[1]</xref><xref ref-type="bibr" rid="article-18105.r3">[3]</xref> With appropriate stewardship and understanding of the risk and benefits of these agents, they can be used in a variety of clinical indications to help maintain the efficacy of many of the broad spectrum bactericidal agents commonly in use in hospitals and outpatient clinics.<xref ref-type="bibr" rid="article-18105.r2">[2]</xref> The level of evidence for the composite studies in this article is I-II.</p>
        <p>The use of these bacteriostatic agents requires an interprofessional team approach to patient care. The prescribing/ordering clinician will decide which antimicrobial to use; this decision should be in tandem with a board-certified infectious disease pharmacist, in conjunction with the latest antibiogram data - especially in the inpatient setting. The pharmacist should also perform a complete medication reconciliation to rule out potential drug-drug interactions. Nursing will be responsible for administering these drugs in the inpatient setting, and for outpatients, they can still counsel the patient on proper administration. Nursing can also evaluate patient adherence and should be cognizant of potential adverse reactions so they can be reported to the prescriber immediately. This interprofessional team approach will optimize the therapeutic potential for bacteriostatic antimicrobials while limiting drug resistance and adverse events. [Level 5]</p>
      </sec>
      <sec id="article-18105.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18105&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18105">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18105/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18105">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18105.s11">
        <title>References</title>
        <ref id="article-18105.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pankey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sabath</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>864</fpage>
            <page-range>864-70</page-range>
            <pub-id pub-id-type="pmid">14999632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemeth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oesch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuster</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>382</fpage>
            <page-range>382-95</page-range>
            <pub-id pub-id-type="pmid">25266070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fridkin</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gaynes</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial resistance in intensive care units.</article-title>
            <source>Clin Chest Med</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-16, viii</page-range>
            <pub-id pub-id-type="pmid">10386258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCabe</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics and endotoxic shock.</article-title>
            <source>Bull N Y Acad Med</source>
            <year>1975</year>
            <month>Oct</month>
            <volume>51</volume>
            <issue>9</issue>
            <fpage>1084</fpage>
            <page-range>1084-95</page-range>
            <pub-id pub-id-type="pmid">1058731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smilack</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The tetracyclines.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>74</volume>
            <issue>7</issue>
            <fpage>727</fpage>
            <page-range>727-9</page-range>
            <pub-id pub-id-type="pmid">10405705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vicente</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Trallero</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Tetracyclines, sulfonamides, and metronidazole].</article-title>
            <source>Enferm Infecc Microbiol Clin</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-30</page-range>
            <pub-id pub-id-type="pmid">20097452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cobos-Trigueros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ateka</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pitart</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vila</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Macrolides and ketolides].</article-title>
            <source>Enferm Infecc Microbiol Clin</source>
            <year>2009</year>
            <season>Aug-Sep</season>
            <volume>27</volume>
            <issue>7</issue>
            <fpage>412</fpage>
            <page-range>412-8</page-range>
            <pub-id pub-id-type="pmid">19625112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeli&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antolovi&#x00107;</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2016</year>
            <month>Sep</month>
            <day>01</day>
            <volume>5</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27598215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smieja</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Current indications for the use of clindamycin: A critical review.</article-title>
            <source>Can J Infect Dis</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-8</page-range>
            <pub-id pub-id-type="pmid">22346533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gudiol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cuervo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pujol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>18</issue>
            <fpage>1947</fpage>
            <page-range>1947-1963</page-range>
            <pub-id pub-id-type="pmid">29115883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Austin</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Beigi</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Meyn</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Hillier</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole.</article-title>
            <source>J Clin Microbiol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>4492</fpage>
            <page-range>4492-7</page-range>
            <pub-id pub-id-type="pmid">16145097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masters</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>O'Bryan</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Zurlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DQ</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Trimethoprim-sulfamethoxazole revisited.</article-title>
            <source>Arch Intern Med</source>
            <year>2003</year>
            <month>Feb</month>
            <day>24</day>
            <volume>163</volume>
            <issue>4</issue>
            <fpage>402</fpage>
            <page-range>402-10</page-range>
            <pub-id pub-id-type="pmid">12588198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guillard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>de La Blanchardi&#x000e8;re</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cattoir</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Verdon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saint-Lorant</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial stewardship and linezolid.</article-title>
            <source>Int J Clin Pharm</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>1059</fpage>
            <page-range>1059-68</page-range>
            <pub-id pub-id-type="pmid">25135806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metaxas</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Update on the safety of linezolid.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>485</fpage>
            <page-range>485-91</page-range>
            <pub-id pub-id-type="pmid">19538105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manfredi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Update on the appropriate use of linezolid in clinical practice.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>455</fpage>
            <page-range>455-64</page-range>
            <pub-id pub-id-type="pmid">18360656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maaland</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Papich</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Turnidge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guardabassi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.</article-title>
            <source>J Clin Microbiol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>3547</fpage>
            <page-range>3547-54</page-range>
            <pub-id pub-id-type="pmid">23966509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratcliffe</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Intravenous macrolide use: a reminder of the dangers of rapid infusion rates.</article-title>
            <source>J Clin Anesth</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>602</fpage>
            <page-range>602-3</page-range>
            <pub-id pub-id-type="pmid">23101782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18105.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Dios Garc&#x000ed;a-D&#x000ed;az</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santolaya Perr&#x000ed;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paz Mart&#x000ed;nez Ortega</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moreno-V&#x000e1;zquez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of erythromycin versus clarithromycin].</article-title>
            <source>Med Clin (Barc)</source>
            <year>2001</year>
            <month>Feb</month>
            <day>03</day>
            <volume>116</volume>
            <issue>4</issue>
            <fpage>133</fpage>
            <page-range>133-5</page-range>
            <pub-id pub-id-type="pmid">11222159</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
